Latest News and Events

September 2018

Nanomerics Announces New Canadian Patent Underpinning its Enkephalin Assets Proceeding to Grant

Nanomerics today announced that the Canadian Intellectual Property Office will allow key patent application underpinning its enkephalin pain therapeutic (patent application number - CA2754140) to proceed to grant.   This patent supports Nanomerics’ pain therapeutics, including NM0127 and provides further assurances to potential partners on patent protection in key markets.  Nanomerics will continue to defend its assets with key patent applications and ongoing patent prosecution.  This is a major component of its business strategy.

August 2018

EPO logo

European Patent Office to Allow the Granting of Two Key Molecular Envelope Technology Patents

Nanomerics today announced the receipt of news that two key patents on its Molecular Envelope Technology (MET) will be granted by the European Patent Office.  

Patent applications EP07789150.5 and EP03748286.6 will be allowed to grant by the European Patent Office, thus further strengthening Nanomerics’ patent portfolio and its business activities in the European Union. These two patents directly underpin Nanomerics’ key drug delivery technology -  Nanomerics’ MET.

February 2018

January 2018

December 2017

NM127 Publication

Towards Better Pain Relief - New Study Published

The US health authorities have recently announced a national emergency related to the use and abuse of opioids estimate by the CDC to cost the US alone $78.5 billion a year and leading to the death of 90 Americans a day [1]. The addictive nature of our current gold standard pain killers for strong pain is central to this crisis and non-addictive alternative medication is urgently needed. Nanomerics NM127 directly addresses these needs.

November 2017

October 2017

Nanomerics Presenting at Epitarget Annual Meeting

Nanomerics' CEO Andreas Schatzlein is presenting new data on the use of the MET platform for the potential treatement of epilepsy at the Epitarget annual meeting in Warsaw (11-13 Oct). Epitarget  (https://www.epitarget.eu) is a large European research consortium funded by the EU under the FP7 framework. Nanomerics has joined this consortium to support the CNS delivery of  novel therapeutics developed by the consortium partners.

Pages